HIV prevention drug  :  billions in corporate profits after millions in taxpayer investments : hearing before the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, first session, May 16, 2019. 
 Human Immunodeficiency Virus prevention drug  Billions in corporate profits after millions in taxpayer investments 

 - 1 online resource (iii, 63 pages) 
<br/><br/> "Serial no. 116-24."  CRDP Program record. 
<br/><br/><label>Subjects--Corporate Names: </label><br/>Gilead Sciences (Firm)
<br/><br/><label>Subjects--Topical Terms: </label><br/>Pre-exposure prophylaxis--Prices--United States.<br/>Pre-exposure prophylaxis--Cost control.--United States<br/>HIV infections--Prevention.--United States<br/>Prescription pricing--Government policy--United States.<br/>Pharmaceutical industry--Prices--Government policy--United States.<br/>Medical policy--United States.<br/>Federal aid to medical research--United States.
<br/><br/><label>Index Terms--Genre/Form: </label><br/>Legislative hearings.
<br/><br/><label>LC Class. No.: </label>KF27  / .O96 2019i 
<br/><br/><label>GPO Item No.: </label>1016-C (online) 
<br/><br/><label>Gov. Doc. Class. No.: </label>Y 4.OV 2:116-24 
<br/><br/><label>Report. No.: </label>Serial no. 116-24 (United States. Congress. House. Committee on Oversight and Reform)